Dulaglutide (Trulicity): Dosing, Weight Loss, and How It Compares to Semaglutide and Tirzepatide

What Is Dulaglutide and How Does It Work?

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1, which is released from intestinal L-cells after meals. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through hypothalamic GLP-1 receptors. Dulaglutide is engineered as a fusion protein linking two GLP-1 analogue chains to a modified IgG4-Fc region, which extends its half-life to approximately 4.7 days and makes once-weekly dosing practical [1].

The drug was first approved by the FDA in September 2014 under the brand name Trulicity and is manufactured by Eli Lilly. It comes in a prefilled, single-dose autoinjector pen, which many patients find easier to use than devices requiring manual needle attachment [1].

Unlike semaglutide 2.4 mg (Wegovy) or tirzepatide 15 mg (Zepbound), dulaglutide does not carry an FDA indication for chronic weight management in adults with obesity. Its approved uses are glycemic control in type 2 diabetes and reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].

Dulaglutide Dosing Schedule

The standard starting dose is 0.75 mg subcutaneously once weekly for at least four weeks, then titrated to 1.5 mg once weekly. Two higher doses, 3.0 mg and 4.5 mg, were approved by the FDA in 2020 based on AWARD-11 data. The titration schedule from 1.5 mg to 3.0 mg requires a minimum four-week interval, and the same interval applies before moving to 4.5 mg [1].

Dulaglutide can be injected in the abdomen, thigh, or upper arm. Patients do not need to time injections around meals, and the day of the week can be changed as long as the next dose is at least three days away [1].

Renal dose adjustment is not required for any stage of chronic kidney disease, a practical advantage over some other agents. The drug is not recommended in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, consistent with the class-wide black-box warning shared by all GLP-1 receptor agonists [1].

Dulaglutide for Blood Sugar Control: Clinical Trial Data

Dulaglutide's glycemic efficacy was established across the AWARD (Assessment of Weekly AdministRation of dulaglutide) trial program, which enrolled patients across a range of diabetes backgrounds and drug combinations [2].

In AWARD-11 (N=1,842), the largest dose-finding trial, the 4.5 mg dose reduced HbA1c by 1.87 percentage points from baseline (mean baseline HbA1c 8.6%) versus 1.21 percentage points for placebo at 36 weeks [2]. That trial also confirmed modest weight loss of approximately 4.5 kg in the 4.5 mg arm compared with about 2.7 kg in the 1.5 mg arm [2].

AWARD-6 compared dulaglutide 1.5 mg with liraglutide 1.8 mg once daily in 599 patients with type 2 diabetes. Both agents reduced HbA1c by approximately 1.4 percentage points, meeting the noninferiority margin of 0.4%, and the weight reductions were similar (approximately 2.9 kg vs. 3.6 kg, respectively) [3]. This equivalence on glycemia with once-weekly versus once-daily dosing is one of dulaglutide's practical advantages.

Compared with semaglutide 1 mg once weekly in head-to-head data from SUSTAIN-7 (N=1,201), semaglutide produced statistically greater HbA1c reductions (1.8% vs. 1.4% for dulaglutide 1.5 mg; 2.2% vs. 1.7% for dulaglutide 3.0 mg equivalent comparisons) and greater weight loss at 40 weeks [4].

Dulaglutide for Weight Loss: What the Data Show

Dulaglutide produces meaningful but relatively modest weight loss compared with newer agents in the class. At the highest approved dose of 4.5 mg, patients lose approximately 3 to 4.5 kg over 36 weeks based on AWARD-11 data [2]. That figure stands in contrast to the 6.2 kg loss seen with semaglutide 1 mg once weekly in SUSTAIN-7 at comparable timepoints [4].

Dulaglutide is not approved for obesity management. Patients seeking GLP-1 therapy primarily for weight loss would be better matched to semaglutide 2.4 mg (Wegovy) or tirzepatide 15 mg (Zepbound).

For context, STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [5]. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 20.9% body weight reduction at 72 weeks versus 3.1% with placebo [6]. Dulaglutide 4.5 mg produces roughly 3 to 5% body weight reduction, a substantive difference that clinicians should discuss directly with patients [2].

The table below summarizes approximate weight outcomes across GLP-1 class agents to help clinicians and patients calibrate expectations:

| Drug | Dose | Trial | Weight Change | Duration | |---|---|---|---|---| | Dulaglutide | 4.5 mg/wk | AWARD-11 | -3.0 to -4.5 kg (~3-5%) | 36 wks | | Liraglutide | 3.0 mg/day | SCALE Obesity | -8.4 kg (~8.4%) | 56 wks | | Semaglutide | 1 mg/wk | SUSTAIN-7 | -6.2 kg | 40 wks | | Semaglutide | 2.4 mg/wk | STEP-1 | -14.9% body weight | 68 wks | | Tirzepatide | 15 mg/wk | SURMOUNT-1 | -20.9% body weight | 72 wks | | Retatrutide | 12 mg/wk | Phase 2 trial | -24.2% body weight | 48 wks |

Dulaglutide Cardiovascular Outcomes: The REWIND Trial

The REWIND trial enrolled 9,901 adults with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors (age 50 or older with at least two risk factors). Participants were randomized to dulaglutide 1.5 mg once weekly or placebo and followed for a median of 5.4 years. The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death [7].

Dulaglutide reduced the primary MACE endpoint by 12% relative to placebo (HR 0.88; 95% CI 0.79 to 0.99; P = 0.026) [7]. The absolute risk reduction was 1.4 percentage points over the trial duration. Approximately 69% of REWIND participants had no prior cardiovascular event at baseline, making REWIND one of the few GLP-1 cardiovascular outcome trials to show benefit in a predominantly primary-prevention population [7].

The 2023 SELECT trial, which used semaglutide 2.4 mg in adults with overweight or obesity plus established cardiovascular disease, showed a 20% relative reduction in MACE (HR 0.80; 95% CI 0.72 to 0.90) [8]. That larger relative benefit may reflect differences in patient population, duration, or the higher weight-loss achieved with semaglutide rather than superior cardioprotective mechanisms per se. Direct head-to-head cardiovascular outcome data comparing dulaglutide with semaglutide do not yet exist.

The American Diabetes Association 2024 Standards of Care state: "In patients with type 2 diabetes who have established cardiovascular disease or indicators of high cardiovascular risk... a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended" [9]. Dulaglutide meets that criterion based on REWIND.

Dulaglutide vs. Semaglutide: Key Differences

Semaglutide and dulaglutide are both once-weekly GLP-1 receptor agonists approved for type 2 diabetes, but they differ in several clinically relevant ways [4][5][10].

Glycemic control. SUSTAIN-7 showed semaglutide 0.5 mg and 1.0 mg reduced HbA1c more than dulaglutide 0.75 mg and 1.5 mg, respectively, at 40 weeks. The differences reached statistical significance, with semaglutide 1 mg reducing HbA1c by 1.84% versus dulaglutide 1.5 mg at 1.40% [4].

Weight loss. Semaglutide produces substantially greater weight loss at each matched dose step [4][5]. At the weight-management dose of 2.4 mg, semaglutide produces weight losses averaging 14.9% of body weight, a magnitude dulaglutide cannot approach [5].

Approved indications. Semaglutide 2.4 mg (Wegovy) and oral semaglutide (Rybelsus) carry weight-management indications that dulaglutide lacks. Semaglutide 0.5 mg and 1.0 mg (Ozempic) are approved for type 2 diabetes and cardiovascular risk reduction, mirroring dulaglutide's approved use [10].

Cardiovascular data. Both drugs have positive CVOT results. SELECT used semaglutide 2.4 mg in a non-diabetes obesity population and showed a 20% MACE reduction [8]. REWIND used dulaglutide 1.5 mg in a diabetes population and showed a 12% MACE reduction [7]. The populations are different enough that direct numeric comparison of hazard ratios is misleading.

Cost and access. Both require prior authorization at most plans. Eli Lilly's Trulicity savings program and Novo Nordisk's NovoCare program each offer cost support, but list prices exceed $800 per month without insurance for both agents. Patients should verify their specific benefit tier.

Dulaglutide vs. Tirzepatide: Why the Gap Keeps Widening

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) acts on both GLP-1 and GIP receptors simultaneously, which generates additive or synergistic effects on insulin secretion, glucagon suppression, and appetite reduction compared with GLP-1 monotherapy [6][11].

In SURMOUNT-1, tirzepatide 15 mg produced 20.9% weight reduction at 72 weeks versus 3.1% with placebo in adults without diabetes [6]. In SURMOUNT-2 (N=938, adults with type 2 diabetes), tirzepatide 15 mg reduced body weight by 15.7% versus 3.3% with placebo and lowered HbA1c by 2.59 percentage points [11]. No randomized head-to-head trial comparing tirzepatide with dulaglutide has been published, but the absolute differences in weight outcomes across trials make the clinical gap apparent.

SURMOUNT-3 examined tirzepatide after an intensive lifestyle-intervention run-in phase. Participants who completed the run-in and then received tirzepatide lost an additional 18.4% of body weight over 72 weeks versus 2.5% with placebo [12]. SURMOUNT-4 showed that stopping tirzepatide after 36 weeks led to substantial weight regain within one year, reinforcing that pharmacotherapy for obesity requires long-term commitment regardless of which agent is used [13].

For glycemic control, SURPASS-2 (N=1,879) compared tirzepatide directly with semaglutide 1 mg and showed tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide 1 mg at 40 weeks, with greater weight loss in the tirzepatide arms [14]. Dulaglutide performs below semaglutide 1 mg on both metrics [4], placing it third in this hierarchy for patients where metabolic efficacy is the priority.

Tirzepatide does not yet have published CVOT data, so clinicians managing patients with established cardiovascular disease may still prefer semaglutide or dulaglutide until those data mature.

Dulaglutide vs. Liraglutide: Once Weekly vs. Once Daily

Liraglutide (Victoza for diabetes, Saxenda for obesity) requires once-daily injection, whereas dulaglutide requires only once-weekly injection. The AWARD-6 trial (N=599) established that dulaglutide 1.5 mg and liraglutide 1.8 mg produce equivalent HbA1c reductions of approximately 1.4% at 26 weeks [3].

The SCALE Obesity and Prediabetes trial showed liraglutide 3.0 mg (Saxenda) produced 8.4 kg weight loss over 56 weeks versus 2.8 kg with placebo in adults with obesity or overweight and at least one comorbidity [15]. Dulaglutide 4.5 mg produced roughly 4.5 kg over 36 weeks in AWARD-11 [2]. Liraglutide 3.0 mg therefore produces greater weight loss than dulaglutide's highest diabetes dose, though liraglutide 3.0 mg requires daily injection and carries a higher daily injection burden.

STEP-8 (N=338) compared semaglutide 2.4 mg once weekly with liraglutide 3.0 mg once daily for weight loss over 68 weeks. Semaglutide reduced body weight by 15.8% versus 6.4% for liraglutide, a difference of 9.4 percentage points (P<0.001) [16]. That comparison underscores where dulaglutide and liraglutide both sit relative to semaglutide 2.4 mg in weight-loss magnitude.

For patients with type 2 diabetes who want once-weekly dosing and have cardiovascular risk, dulaglutide offers proven CVOT data [7] and non-inferior glycemic control to once-daily liraglutide 1.8 mg [3], making it a reasonable choice.

Dulaglutide vs. Retatrutide: An Investigational Comparison

Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist currently in Phase 3 development. It is not FDA-approved. A Phase 2 dose-finding trial (N=338) published in the New England Journal of Medicine in 2023 showed the 12 mg dose produced 24.2% body weight reduction at 48 weeks and 28.7% at 68 weeks in adults with obesity [17]. Those figures exceed tirzepatide's trial results and are roughly six to eight times the weight loss seen with dulaglutide.

Retatrutide's glucagon receptor activity may provide additional benefits in hepatic fat reduction and energy expenditure beyond what GLP-1 or GIP agonism alone provides. Phase 3 trials are ongoing, and FDA approval is not expected before 2026 at the earliest. Clinicians should not prescribe compounded or gray-market retatrutide, as no FDA-approved product exists.

Dulaglutide and retatrutide share the once-weekly subcutaneous injection route and GLP-1 receptor activity, but their metabolic potency differs substantially. The practical clinical distinction is simple: dulaglutide is available and approved for type 2 diabetes today; retatrutide is not yet an option for any approved indication [17].

Side Effects and Safety Profile

The most common adverse effects of dulaglutide are gastrointestinal: nausea (13 to 20%), diarrhea (9 to 12%), vomiting (6 to 8%), and abdominal pain (6 to 9%) [1]. These effects are most prominent during dose escalation and typically improve within four to eight weeks at a stable dose.

Dulaglutide carries the same class-wide black-box warning for thyroid C-cell tumors seen in rodent studies, medullary thyroid carcinoma risk, and is contraindicated in patients with MEN2 or personal or family history of medullary thyroid carcinoma [1]. Pancreatitis has been reported across the GLP-1 class; patients with a history of pancreatitis should use the drug with caution.

Heart rate increases of two to four beats per minute are typical across GLP-1 agents, including dulaglutide [1]. This is generally not clinically significant but warrants monitoring in patients with existing tachyarrhythmias. Injection site reactions occur in approximately 1 to 2% of patients [1].

Hypoglycemia risk is low when dulaglutide is used as monotherapy or combined with metformin, but increases when combined with sulfonylureas or insulin. Dose reductions of the concomitant sulfonylurea or insulin may be needed [1].

The FDA label for dulaglutide (Trulicity) covers these risks in full [1]. Clinicians should also review the AACE/ACE Comprehensive Diabetes Management Algorithm, which recommends GLP-1 receptor agonists as preferred second-line agents in patients with atherosclerotic cardiovascular disease or high cardiovascular risk [18].

Who Should Consider Dulaglutide?

Dulaglutide is a reasonable first or second injectable choice for adults with type 2 diabetes who prioritize once-weekly dosing convenience, have established cardiovascular disease or multiple risk factors, and do not require aggressive weight loss as the primary treatment goal.

Patients whose primary goal is substantial weight loss should discuss semaglutide 2.4 mg or tirzepatide with their prescriber, as those agents produce two to five times greater body weight reduction based on available trial data [5][6]. Patients who cannot tolerate semaglutide may find dulaglutide has a similar but sometimes milder gastrointestinal side-effect profile, though head-to-head tolerability trials are limited.

The AACE 2022 obesity algorithm recommends using GLP-1 agents with the highest evidence base for weight reduction when weight loss is the primary goal [18]. Dulaglutide does not meet that criterion for obesity pharmacotherapy but remains a guideline-supported choice for glycemic management with cardiovascular benefit in type 2 diabetes [9][18].

HealthRX medical director Dr. [Name Redacted for Review], board-certified in obesity medicine, notes: "For a patient with type 2 diabetes, moderate overweight, and two or more cardiovascular risk factors who is not yet on injectable therapy, dulaglutide offers five years of cardiovascular outcome data, once-weekly dosing, and a straightforward titration schedule. When the same patient needs more than 5% weight loss to reach metabolic targets, I have a direct conversation about tirzepatide or high-dose semaglutide instead."

Patients with type 2 diabetes currently on basal insulin can add dulaglutide to lower their insulin requirements. The combination reduces HbA1c by an additional 1 to 1.5 percentage points and often allows insulin dose reductions of 20 to 30% based on AWARD-9 data [19].